A Phase 1, First-in-human Study of VX-433
Key facts
- Where
- Salt Lake City, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT07584434, who can take part
Where in United States
- ICON - Utah - Salt Lake City OfficeSalt Lake City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Trial code
- NCT07584434
- Record updated
- 8 June 2026
- Original description
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.Read full original descriptionShow less
A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
Inclusion: Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m2), inclusive; A total body weight of more than (>) 50 kg; Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening.
Exclusion: History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug; For female participants: of childbearing potential, pregnant, breastfeeding, or planning to become pregnant or donate ova during the study or within 90 days after last dose of study drug; Other protocol defined Inclusion/Exclusion criteria will apply; Any condition possibly affecting drug absorption.